Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
pacira.com

See what CB Insights has to offer

Founded Year

2007

Stage

IPO | IPO

Total Raised

$111.25M

Date of IPO

4/13/2012

Market Cap

2.34B

Stock Price

52.53

About Pacira Biosciences

Pacira Biosciences is focused on formulating, developing and manufacturing controlled-release injectable products based on two drug delivery platforms: DepoFoam and Biosphere. Currently the Company is generating revenue with two marketed products: DepoCyt for lymphomatous meningitis and DepoDur for the treatment of post-surgical pain.

Pacira Biosciences Headquarter Location

10578 Science Center Drive Suite 125

San Diego, California, 92121,

United States

858-625-2424

Latest Pacira Biosciences News

07:30 ET CODA Biotherapeutics Closes $28 Million Financing led by Pacira BioSciences

Dec 2, 2021

Includes participation from existing investors - MPM Capital and Versant Ventures Leading non-opioid pain management company Pacira BioSciences joins as equity investor in CODA's chemogenetic gene therapy platform to treat neurological disorders News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., Dec. 2, 2021 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders with an initial focus on neuropathic pain and epilepsy, today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc., together with the company's existing investors, MPM Capital and Versant Ventures, and a new venture debt round with Silicon Valley Bank (SVB). As part of the financing, David Stack, chairman and CEO of Pacira Biosciences, has joined CODA's board of directors. "We are pleased to have Pacira BioSciences join our existing investors in supporting our mission to develop novel chemogenetic therapies for the treatment of neurological disorders for which current treatment options have significant limitations," said Michael Narachi, president and CEO of CODA. "We have significantly increased our cash balances to fuel continued progress on our platform with an initial focus on neuropathic pain and focal epilepsy. The equity investment capital from Pacira BioSciences, one of the world's leading non-opioid pain management companies, further validates our approach and will help us progress our neuropathic pain therapies toward human clinical trials where we hope to demonstrate transformative results for patients." "We are extremely excited to back the CODA team and their groundbreaking chemogenetic gene therapy platform," said Mr. Stack. "We believe the CODA approach could transform the treatment paradigm for neuropathic pain and help millions of patients." About the CODA Platform  CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach by deploying a chemogenetic strategy for treating neurological disorders. The Company's innovative treatment aims to modulate specific neuronal circuits via adeno-associated virus (AAV)-mediated delivery of an engineered, inhibitory receptor by standard-of-care neurosurgical procedures. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable results while potentially avoiding off-target/adverse effects of currently available treatments. About Neuropathic Pain and Focal Epilepsy  According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain – an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction. Epilepsy is one of the most common chronic neurological diseases and, according to the Centers for Disease Control, affects more than 65 million people around the world of which 3.4 million are in the U.S. Epilepsy is characterized by unpredictable seizures and the term "focal" epilepsy is used to describe seizures that initiate from a specific location in the brain, typically in one hemisphere. Focal epilepsy represents approximately 60 percent of all epilepsy (National Institute of Neurological Disorders and Strokes). According to the World Health Organization, recurrent seizures disrupt normal brain functions, lead to neuronal loss, and result in cognitive and emotional deficits. Patients suffer from stigmatization, social isolation, combined with disability, educational underachievement, and poor employment outcomes. The Epilepsy Foundation estimates that one-third of people with epilepsy live with uncontrollable seizures because no available treatments are effective. About CODA Biotherapeutics   CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit www.codabiotherapeutics.com . SOURCE CODA Biotherapeutics, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pacira Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pacira Biosciences is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Pacira Biosciences Patents

Pacira Biosciences has filed 12 patents.

The 3 most popular patent topics include:

  • Anesthesia
  • Analgesics
  • Calcium channel blockers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/13/2021

11/30/2021

Anesthesia, Membrane technology, Analgesics, Piperidines, Calcium channel blockers

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Anesthesia, Membrane technology, Analgesics, Piperidines, Calcium channel blockers

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Pacira Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pacira Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.